NCT05516914 2025-11-28
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
Nanjing Leads Biolabs Co.,Ltd
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Eisai Inc.